周四盘中，港股上市的创新药企业荣昌生物（09995）股价大幅下挫，截至10时18分，跌幅达到10.88%。这一跌势不仅远超过其他同行，也引发了市场对生物制药行业前景的担忧。
从行业整体来看，当日港股创新药概念股普遍呈现震荡走弱态势。除荣昌生物外，昭衍新药、石药集团等多家公司股价也出现不同程度的下跌，反映出投资者对该板块的谨慎情绪。这种广泛性的下跌可能与行业面临的挑战有关，如研发成本高昂、审批周期长等因素。
具体到荣昌生物，公司最新的财务报告显示，虽然2025年上半年主营收入同比增长48.02%达到10.98亿元，但仍录得4.5亿元的净亏损。尽管亏损幅度较去年同期收窄，但持续的亏损状态可能引发投资者对公司盈利能力的担忧。此外，近期资金流向数据显示，主力资金呈现净流出态势，这可能加剧了股价的下跌压力。值得注意的是，尽管当前股价表现不佳，但多数机构仍对荣昌生物保持积极评级，显示出对公司长期发展前景的信心。然而，市场短期内对生物制药行业的审慎态度可能继续影响荣昌生物的股价表现。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.